A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer
Saved in:
Main Authors: | Ji‐Yong Sung, Jae‐Ho Cheong, Kihye Shin, Eui Tae Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-12-01
|
Series: | Clinical and Translational Medicine |
Online Access: | https://doi.org/10.1002/ctm2.70079 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overexpression of FERM Domain Containing Kindlin 2 (FERMT2) in Fibroblasts Correlates with EMT and Immunosuppression in Gastric Cancer
by: Sheng-yan Yin, et al.
Published: (2024-01-01) -
Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
by: Mikito Inokuchi, et al.
Published: (2015-01-01) -
Dual-positive gastric cancer: an extremely malignant subtype of gastric cancer with high serum alpha-fetoprotein and carcinoembryonic antigen concentrations
by: Weixun Xie, et al.
Published: (2025-01-01) -
PDPN+ cancer‐associated fibroblasts enhance gastric cancer angiogenesis via AKT/NF‐κB activation and the CCL2‐ACKR1 axis
by: Zhenxiong Zhao, et al.
Published: (2025-01-01) -
COX-2 Inhibitors and Gastric Cancer
by: Zhen Wang, et al.
Published: (2014-01-01)